by Raynovich Rod | Oct 25, 2013 | 2024 Rayno Biopharmaceuticals Portfolio
Biopharmaceutical stocks were somewhat mixed today yet we have some nice moves in our portfolio: Alexion (ALXN $125.26) up 7.34% on Q3 Results which showed a 36% increase in sales to $400M and Net Income (GAAP) of $93.8M up from $92.2M in the same quarter of 2012. The...
by Raynovich Rod | Oct 9, 2013 | Biopharmaceuticals
Are Biotech Valuations in the “Bubblet” Phase? In September of 2013 we wrote about the valuations of biotechnology companies from an M&A perspective after the acquisition of Onyx Pharmaceuticals (ONXX) by Amgen at a price of $10.4B. We will attempt to...
by Raynovich Rod | Oct 1, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Stocks Hit New Highs Unfazed By Shutdown Biopharmaceutical stocks continued their blazing Q3 run today buoyed by assumptions that demand for pharmaceuticals will increase with 55 million new potential patients from Obamacare and that healthcare stocks are less...
by Raynovich Rod | Sep 3, 2013 | Biopharmaceuticals
(Published this am in Seeking Alpha) Onyx Pharmaceuticals (ONXX) $10.4B Buy-Out Fuels Speculative Deal Lists We have written extensively on the life science bull market and its underpinnings: cheap money, scientific breakthroughs, sales growth and of course, M&A....
by Raynovich Rod | Aug 1, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Biotech ETF (IBB) Hits New High of $200-Mid Caps Get Turbo Boost Positive Economic Data Helps The life science sector roared ahead again today helped by a 1% move in NASDAQ now at YTD highs up 21%. With an earlier post last week we urged “staying the...
by Raynovich Rod | Jun 20, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Rayno Diagnostics and Tools Portfolio Prices as of 5/29/13 Top 2013 Winners: ABAX, ALR, CSII, GHDX, ILMN, TMO, VRML Sector high was in mid-May Less volatile than biopharma but more dependent on earnings Five companies on focus list were acquired over 3 years...
by Raynovich Rod | Jun 5, 2013 | BIOgraph, Biopharmaceuticals
Market Correction Is Here-IBB at 170 off 2%+ The biotech sector sell-off (IBB at $170) continues today despite an effort to rally in the opening (IBB at $178). The biotech sector now tracks the overall market and is no longer immune to macro issues and economic...
by Raynovich Rod | Jun 4, 2013 | BIOgraph, Biopharmaceuticals
Apparently ASCO Is “Sell On the News” Trigger Another lackluster trading day with profit taking; the IBB is down 2.3% and trading near its May bottom with a pronounced topping pattern.Moreover many funds and indices now own biotech stocks so without the...
by Raynovich Rod | May 21, 2013 | 2024 Rayno Biopharmaceuticals Portfolio
Biopharmaceutical Stocks Rally- Many Rayno Picks up 2%+ If the past four days was the long awaited biotechnology correction it was barely noticeable, a mere 3.7% high to low over the past week.Today the rally has resumed with major large cap holdings from funds and...
by Raynovich Rod | May 14, 2013 | BIOgraph, Biopharmaceuticals
BioBubble with No Trouble? Another green screen today with the usual suspects running in Rayno Biopharmaceuticals helped by the Bank of America Health Care Conference. Alexion (ALXN) up 2.86%, Biogen Idec (BIIB) up 3.19%, Gilead (GILD) up 3.27%, Pharmacyclics (PCYC)...